Pub Date : 2023-12-21DOI: 10.1016/j.bbcan.2023.189061
Bailey K. Roberts , Gilbert Collado , Betsy J. Barnes
Canonically, the transcription factor interferon regulatory factor 5 (IRF5) is a key mediator of innate and adaptive immunity downstream of pathogen recognition receptors such as Toll-like receptors (TLRs). Hence, dysregulation of IRF5 function has been widely implicated in inflammatory and autoimmune diseases. Over the last few decades, dysregulation of IRF5 expression has been also reported in hematologic malignancies and solid cancers that support a role for IRF5 in malignant transformation, tumor immune regulation, clinical prognosis, and treatment response. This review will provide an in-depth overview of the current literature regarding the mechanisms by which IRF5 functions as either a tumor suppressor or oncogene, its role in metastasis, regulation of the tumor-immune microenvironment, utility as a prognostic indicator of disease, and new developments in IRF5 therapeutics that may be used to remodel tumor immunity.
{"title":"Role of interferon regulatory factor 5 (IRF5) in tumor progression: Prognostic and therapeutic potential","authors":"Bailey K. Roberts , Gilbert Collado , Betsy J. Barnes","doi":"10.1016/j.bbcan.2023.189061","DOIUrl":"10.1016/j.bbcan.2023.189061","url":null,"abstract":"<div><p><span><span><span><span>Canonically, the transcription factor interferon regulatory factor 5 (IRF5) is a key mediator of innate and adaptive immunity downstream of </span>pathogen recognition receptors such as Toll-like receptors (TLRs). Hence, dysregulation of IRF5 function has been widely implicated in inflammatory and autoimmune diseases. Over the last few decades, dysregulation of IRF5 expression has been also reported in </span>hematologic malignancies<span> and solid cancers that support a role for IRF5 in malignant transformation<span>, tumor immune regulation, clinical prognosis, and treatment response. This review will provide an in-depth overview of the current literature regarding the mechanisms by which IRF5 functions as either a </span></span></span>tumor suppressor or </span>oncogene<span>, its role in metastasis<span>, regulation of the tumor-immune microenvironment, utility as a prognostic indicator of disease, and new developments in IRF5 therapeutics that may be used to remodel tumor immunity.</span></span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138825921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-17DOI: 10.1016/j.bbcan.2023.189058
Aihong Wang , Yin Wang , Chenxiang Du , Huilun Yang , Zhengping Wang , Canhui Jin , Michael R. Hamblin
Ovarian cancer is a less common tumor in women compared to cervical or breast cancer, however it is more malignant and has worse outcomes. Ovarian cancer patients still have a five-year survival rate < 50% despite advances in therapy. Due to recent developments in immune checkpoint inhibitors (ICIs), cancer immunotherapy has attracted increased interest. Pyroptosis is a highly inflammatory form of cell death, which is essential for bridging innate and adaptive immunity, and is involved in immune regulation within the tumor microenvironment (TME). Recent research has shown that pyroptosis can promote immunotherapy of ovarian cancer, including treatment with chimeric antigen receptor T-cells (CAR-T) or ICIs. Moreover, inflammasomes, various signaling pathways and lncRNAs can all affect pyroptosis in ovarian cancer. Here we discuss how pyroptosis affects the development and progression of ovarian cancer as well as the TME. We also provide a summary of small molecule drugs that could target pyroptotic cell death processes and may be useful in ovarian cancer therapy.
与宫颈癌或乳腺癌相比,卵巢癌是女性中较少见的肿瘤,但其恶性程度更高,预后更差。尽管治疗手段不断进步,但卵巢癌患者的五年生存率仍只有 50%。由于免疫检查点抑制剂(ICIs)的最新进展,癌症免疫疗法引起了越来越多的关注。热噬是一种高度炎症性的细胞死亡形式,对于连接先天性免疫和适应性免疫至关重要,并参与肿瘤微环境(TME)内的免疫调节。最近的研究表明,化脓过程可促进卵巢癌的免疫治疗,包括嵌合抗原受体 T 细胞(CAR-T)或 ICIs 治疗。此外,炎性体、各种信号通路和lncRNAs都会影响卵巢癌的化脓过程。在此,我们将讨论热蛋白沉积如何影响卵巢癌的发生和发展以及TME。我们还总结了可靶向热噬细胞死亡过程的小分子药物,这些药物可能有助于卵巢癌的治疗。
{"title":"Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment","authors":"Aihong Wang , Yin Wang , Chenxiang Du , Huilun Yang , Zhengping Wang , Canhui Jin , Michael R. Hamblin","doi":"10.1016/j.bbcan.2023.189058","DOIUrl":"10.1016/j.bbcan.2023.189058","url":null,"abstract":"<div><p><span><span><span><span>Ovarian cancer is a less common tumor in women compared to cervical or breast cancer, however it is more malignant and has worse outcomes. Ovarian cancer patients still have a five-year survival rate < 50% despite advances in therapy. Due to recent developments in immune checkpoint inhibitors (ICIs), </span>cancer immunotherapy<span> has attracted increased interest. Pyroptosis is a highly inflammatory form of </span></span>cell death<span><span><span>, which is essential for bridging innate and adaptive immunity, and is involved in immune regulation within the </span>tumor microenvironment<span> (TME). Recent research has shown that pyroptosis can promote immunotherapy of ovarian cancer, including </span></span>treatment with chimeric antigen receptor T-cells (CAR-T) or ICIs. Moreover, </span></span>inflammasomes<span><span>, various signaling pathways and lncRNAs can all affect pyroptosis in ovarian cancer. Here we discuss how pyroptosis affects the development and progression of ovarian cancer as well as the TME. We also provide a summary of </span>small molecule </span></span>drugs that could target pyroptotic cell death processes and may be useful in ovarian cancer therapy.</p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glioblastoma multiforme is a highly malignant brain tumor with significant intra- and intertumoral heterogeneity known for its aggressive nature and poor prognosis. The complex signaling cascade that regulates this heterogeneity makes targeted drug therapy ineffective. The development of an optimal preclinical model is crucial for the comprehension of molecular heterogeneity and enhancing therapeutic efficacy. The ideal model should establish a relationship between various oncogenes and their corresponding responses. This review presents an analysis of preclinical in vivo and in vitro models that have contributed to the advancement of knowledge in model development. The experimental designs utilized in vivo models consisting of both immunodeficient and immunocompetent mice induced with intracranial glioma. The transgenic model was generated using various techniques, like the viral vector delivery system, transposon system, Cre-LoxP model, and CRISPR-Cas9 approaches. The utilization of the patient-derived xenograft model in glioma research is valuable because it closely replicates the human glioma microenvironment, providing evidence of tumor heterogeneity. The utilization of in vitro techniques in the initial stages of research facilitated the comprehension of molecular interactions. However, these techniques are inadequate in reproducing the interactions between cells and extracellular matrix (ECM). As a result, bioengineered 3D-in vitro models, including spheroids, scaffolds, and brain organoids, were developed to cultivate glioma cells in a three-dimensional environment. These models have enabled researchers to understand the influence of ECM on the invasive nature of tumors. Collectively, these preclinical models effectively depict the molecular pathways and facilitate the evaluation of multiple molecules while tailoring drug therapy.
{"title":"Glioblastoma preclinical models: Strengths and weaknesses","authors":"Vasavi Pasupuleti , Lalitkumar Vora , Renuka Prasad , D.N. Nandakumar , Dharmendra Kumar Khatri","doi":"10.1016/j.bbcan.2023.189059","DOIUrl":"10.1016/j.bbcan.2023.189059","url":null,"abstract":"<div><p>Glioblastoma multiforme is a highly malignant brain tumor with significant intra- and intertumoral heterogeneity known for its aggressive nature and poor prognosis. The complex signaling cascade that regulates this heterogeneity makes targeted drug therapy ineffective. The development of an optimal preclinical model is crucial for the comprehension of molecular heterogeneity and enhancing therapeutic efficacy. The ideal model should establish a relationship between various oncogenes and their corresponding responses. This review presents an analysis of preclinical <em>in vivo</em> and <em>in vitro</em> models that have contributed to the advancement of knowledge in model development. The experimental designs utilized <em>in vivo</em> models consisting of both immunodeficient and immunocompetent mice induced with intracranial glioma. The transgenic model was generated using various techniques, like the viral vector delivery system, transposon system, Cre-LoxP model, and CRISPR-Cas9 approaches. The utilization of the patient-derived xenograft model in glioma research is valuable because it closely replicates the human glioma microenvironment, providing evidence of tumor heterogeneity. The utilization of <em>in vitro</em> techniques in the initial stages of research facilitated the comprehension of molecular interactions. However, these techniques are inadequate in reproducing the interactions between cells and extracellular matrix (ECM). As a result, bioengineered 3D-<em>in vitro</em> models, including spheroids, scaffolds, and brain organoids, were developed to cultivate glioma cells in a three-dimensional environment. These models have enabled researchers to understand the influence of ECM on the invasive nature of tumors. Collectively, these preclinical models effectively depict the molecular pathways and facilitate the evaluation of multiple molecules while tailoring drug therapy.</p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0304419X23002081/pdfft?md5=0ad13b3f7a99d08bcb0f917b8fc0b173&pid=1-s2.0-S0304419X23002081-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-15DOI: 10.1016/j.bbcan.2023.189055
Quincy C.C. van den Bosch , Annelies de Klein , Robert M. Verdijk , Emine Kiliç , Erwin Brosens , on behalf of the Rotterdam Ocular Melanoma Study Group
Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology have been extensively studied, there are significant gaps in our understanding of the early stages of UM tumor evolution and effective treatment to prevent metastatic disease remain elusive. A better understanding of the mechanisms that enable UM cells to thrive and successfully metastasize is crucial to improve treatment efficacy and survival rates. For more than forty years, animal models have been used to investigate the biology of UM. This has led to a number of essential mechanisms and pathways involved in UM aetiology. These models have also been used to evaluate the effectiveness of various drugs and treatment protocols. Here, we provide an overview of the molecular mechanisms and pharmacological studies using mouse and zebrafish UM models. Finally, we highlight promising therapeutics and discuss future considerations using UM models such as optimal inoculation sites, use of BAP1mut-cell lines and the rise of zebrafish models.
尽管进行了广泛的研究并改进了治疗方案,但转移性葡萄膜黑色素瘤(UM)患者的生存率并没有显著提高。葡萄膜黑色素瘤是一种起源于葡萄膜道黑色素细胞的恶性肿瘤,可能没有任何症状,而且只有在常规眼科检查中才能发现小肿瘤,因此很难早期发现和治疗。UM是多种特征性体细胞改变的结果,与预后有关。尽管对 UM 的形态学和生物学进行了广泛的研究,但我们对 UM 肿瘤演变早期阶段的了解仍有很大的差距,而且预防转移性疾病的有效治疗方法仍难以实现。更好地了解使 UM 细胞茁壮成长并成功转移的机制对于提高治疗效果和生存率至关重要。四十多年来,动物模型一直被用于研究 UM 的生物学特性。这导致了许多涉及 UM 病因学的基本机制和途径。这些模型还被用于评估各种药物和治疗方案的有效性。在此,我们将概述使用小鼠和斑马鱼 UM 模型进行的分子机制和药理学研究。最后,我们重点介绍了有前景的治疗方法,并讨论了未来使用 UM 模型的注意事项,如最佳接种部位、BAP1 突变细胞系的使用和斑马鱼模型的兴起。
{"title":"Uveal melanoma modeling in mice and zebrafish","authors":"Quincy C.C. van den Bosch , Annelies de Klein , Robert M. Verdijk , Emine Kiliç , Erwin Brosens , on behalf of the Rotterdam Ocular Melanoma Study Group","doi":"10.1016/j.bbcan.2023.189055","DOIUrl":"10.1016/j.bbcan.2023.189055","url":null,"abstract":"<div><p>Despite extensive research and refined therapeutic options, the survival for metastasized uveal melanoma (UM) patients has not improved significantly. UM, a malignant tumor originating from melanocytes in the uveal tract, can be asymptomatic and small tumors may be detected only during routine ophthalmic exams; making early detection and treatment difficult. UM is the result of a number of characteristic somatic alterations which are associated with prognosis. Although UM morphology and biology have been extensively studied, there are significant gaps in our understanding of the early stages of UM tumor evolution and effective treatment to prevent metastatic disease remain elusive. A better understanding of the mechanisms that enable UM cells to thrive and successfully metastasize is crucial to improve treatment efficacy and survival rates. For more than forty years, animal models have been used to investigate the biology of UM. This has led to a number of essential mechanisms and pathways involved in UM aetiology. These models have also been used to evaluate the effectiveness of various drugs and treatment protocols. Here, we provide an overview of the molecular mechanisms and pharmacological studies using mouse and zebrafish UM models. Finally, we highlight promising therapeutics and discuss future considerations using UM models such as optimal inoculation sites, use of <em>BAP1</em><sup>mut</sup>-cell lines and the rise of zebrafish models.</p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0304419X23002044/pdfft?md5=ce21cbe5e5f2614fcd8cc5a3da9de5c1&pid=1-s2.0-S0304419X23002044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-14DOI: 10.1016/j.bbcan.2023.189054
Magdalena Kusaczuk , Elena Tovar Ambel , Monika Naumowicz , Guillermo Velasco
Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in GBM therapy has gained a great deal of attention, since depending on the duration and intensity of these cellular programs they can be cytoprotective or promote cancer cell death. As such, initiation of the UPR, autophagy or oxidative stress may either impede or facilitate drug-mediated cell killing. In this review, we summarize the mechanisms that regulate ER stress, autophagy, and oxidative stress during GBM development and progression to later discuss the involvement of these stress pathways in the response to different treatments. We also discuss how a precise understanding of the molecular mechanisms regulating stress responses evoked by different pharmacological agents could decisively contribute to the design of novel and more effective combinational treatments against brain malignancies.
尽管人们一直在努力寻找有效的治疗策略,但胶质母细胞瘤(GBM)仍然是一个治疗难题,预后存活率很低。在过去十年中,应激反应在 GBM 治疗中的作用受到了广泛关注,因为根据这些细胞程序的持续时间和强度,它们可以起到细胞保护作用,也可以促进癌细胞死亡。因此,UPR、自噬或氧化应激的启动可能会阻碍或促进药物介导的细胞杀伤。在这篇综述中,我们总结了在 GBM 的发展和进展过程中调节 ER 应激、自噬和氧化应激的机制,随后讨论了这些应激途径在不同治疗反应中的参与情况。我们还讨论了精确了解不同药剂诱发的应激反应的分子调控机制将如何决定性地促进针对脑部恶性肿瘤的新型、更有效的联合疗法的设计。
{"title":"Cellular stress responses as modulators of drug cytotoxicity in pharmacotherapy of glioblastoma","authors":"Magdalena Kusaczuk , Elena Tovar Ambel , Monika Naumowicz , Guillermo Velasco","doi":"10.1016/j.bbcan.2023.189054","DOIUrl":"10.1016/j.bbcan.2023.189054","url":null,"abstract":"<div><p>Despite the extensive efforts to find effective therapeutic strategies, glioblastoma (GBM) remains a therapeutic challenge with dismal prognosis of survival. Over the last decade the role of stress responses in GBM therapy has gained a great deal of attention, since depending on the duration and intensity of these cellular programs they can be cytoprotective or promote cancer cell death. As such, initiation of the UPR, autophagy or oxidative stress may either impede or facilitate drug-mediated cell killing. In this review, we summarize the mechanisms that regulate ER stress, autophagy, and oxidative stress during GBM development and progression to later discuss the involvement of these stress pathways in the response to different treatments. We also discuss how a precise understanding of the molecular mechanisms regulating stress responses evoked by different pharmacological agents could decisively contribute to the design of novel and more effective combinational treatments against brain malignancies.</p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0304419X23002032/pdfft?md5=22fefd7b16d45de109e97f7941e25599&pid=1-s2.0-S0304419X23002032-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-13DOI: 10.1016/j.bbcan.2023.189051
Gloria Pascual , Blanca Majem , Salvador Aznar-Benitah
This review delves into the most recent research on the metabolic adaptability of cancer cells and examines how their metabolic functions can impact their progression into metastatic forms. We emphasize the growing significance of lipid metabolism and dietary lipids within the tumor microenvironment, underscoring their influence on tumor progression. Additionally, we present an outline of the interplay between metabolic processes and the epigenome of cancer cells, underscoring the importance regarding the metastatic process. Lastly, we examine the potential of targeting metabolism as a therapeutic approach in combating cancer progression, shedding light on innovative drugs/targets currently undergoing preclinical evaluation.
{"title":"Targeting lipid metabolism in cancer metastasis","authors":"Gloria Pascual , Blanca Majem , Salvador Aznar-Benitah","doi":"10.1016/j.bbcan.2023.189051","DOIUrl":"10.1016/j.bbcan.2023.189051","url":null,"abstract":"<div><p>This review delves into the most recent research on the metabolic adaptability of cancer cells<span><span> and examines how their metabolic functions can impact their progression into metastatic forms. We emphasize the growing significance of lipid metabolism and dietary </span>lipids<span><span> within the tumor microenvironment, underscoring their influence on tumor progression. Additionally, we present an outline of the interplay between metabolic processes and the </span>epigenome of cancer cells, underscoring the importance regarding the metastatic process. Lastly, we examine the potential of targeting metabolism as a therapeutic approach in combating cancer progression, shedding light on innovative drugs/targets currently undergoing preclinical evaluation.</span></span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer patients are often diagnosed with venous thromboembolism (VTE), a cardiovascular disease that substantially decreases their quality of life and survival rate. Haemostasis in these patients is deregulated, which is reflected in the common presentation of a blood hypercoagulation state. Despite the inconsistent results, existing evidence suggests that the expression of microRNAs (miRNAs) is deregulated in the context of venous thrombogenesis in the general population. However, few miRNAs are known to be linked to cancer-associated VTE due to the lack of studies with oncological patients. Parallelly, coagulation factor III, also known as tissue factor (TF), tissue factor pathway inhibitor 1 (TFPI1) and tissue factor pathway inhibitor 2 (TFPI2) have been proposed to have a central role in cancer-associated VTE and tumour progression. Yet, contrary to what was expected, the role of miRNAs targeting the TF coagulation pathway (or extrinsic coagulation pathway) is poorly explored in cancer-induced thrombogenesis. In this review, in addition to miRNAs implicated in VTE, TF and TFPI1/2-targeting miRNAs were revised. Future studies should clarify the implications of these non-coding RNAs in tumour coagulome.
{"title":"Cancer-associated thrombosis: What about microRNAs targeting the tissue factor coagulation pathway?","authors":"Valéria Tavares , Beatriz Vieira Neto , Inês Soares Marques , Joana Assis , Deolinda Pereira , Rui Medeiros","doi":"10.1016/j.bbcan.2023.189053","DOIUrl":"10.1016/j.bbcan.2023.189053","url":null,"abstract":"<div><p><span><span>Cancer patients are often diagnosed with venous thromboembolism<span> (VTE), a cardiovascular disease that substantially decreases their quality of life<span> and survival rate. Haemostasis in these patients is deregulated, which is reflected in the common presentation of a blood hypercoagulation state. Despite the inconsistent results, existing evidence suggests that the expression of </span></span></span>microRNAs (miRNAs) is deregulated in the context of venous </span>thrombogenesis<span> in the general population. However, few miRNAs are known to be linked to cancer-associated VTE due to the lack of studies with oncological patients. Parallelly, coagulation factor<span> III, also known as tissue factor<span> (TF), tissue factor pathway inhibitor 1 (TFPI1) and tissue factor pathway inhibitor 2 (TFPI2) have been proposed to have a central role in cancer-associated VTE and tumour progression. Yet, contrary to what was expected, the role of miRNAs targeting the TF coagulation pathway (or extrinsic coagulation pathway) is poorly explored in cancer-induced thrombogenesis. In this review, in addition to miRNAs implicated in VTE, TF and TFPI1/2-targeting miRNAs were revised. Future studies should clarify the implications of these non-coding RNAs in tumour coagulome.</span></span></span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138573353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-12DOI: 10.1016/j.bbcan.2023.189052
Vanja Tadić , Wei Zhang , Anamaria Brozovic
High-grade serous ovarian cancer (HGSOC) is the most frequent and aggressive type of epithelial ovarian cancer, with high recurrence rate and chemoresistance being the main issues in its clinical management. HGSOC is specifically challenging due to the metastatic dissemination via spheroids in the ascitic fluid. The HGSOC spheroids represent the invasive and chemoresistant cellular fraction, which is impossible to investigate in conventional two-dimensional (2D) monolayer cell cultures lacking critical cell-to-cell and cell-extracellular matrix interactions. Three-dimensional (3D) HGSOC cultures, where cells aggregate and exhibit relevant interactions, offer a promising in vitro model of peritoneal metastasis and multicellular drug resistance. This review summarizes recent studies of HGSOC in 3D culture conditions and highlights the role of multicellular HGSOC spheroids and ascitic environment in HGSOC metastasis and chemoresistance.
{"title":"The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models","authors":"Vanja Tadić , Wei Zhang , Anamaria Brozovic","doi":"10.1016/j.bbcan.2023.189052","DOIUrl":"10.1016/j.bbcan.2023.189052","url":null,"abstract":"<div><p><span>High-grade serous ovarian cancer (HGSOC) is the most frequent and aggressive type of epithelial ovarian cancer, with high recurrence rate and chemoresistance being the main issues in its clinical management. HGSOC is specifically challenging due to the metastatic dissemination </span><em>via</em><span><span> spheroids in the ascitic fluid. The HGSOC spheroids represent the invasive and chemoresistant cellular fraction, which is impossible to investigate in conventional two-dimensional (2D) monolayer cell cultures lacking critical cell-to-cell and cell-extracellular matrix interactions. Three-dimensional (3D) </span>HGSOC cultures, where cells aggregate and exhibit relevant interactions, offer a promising </span><em>in vitro</em><span> model of peritoneal metastasis<span> and multicellular drug resistance. This review summarizes recent studies of HGSOC in 3D culture conditions and highlights the role of multicellular HGSOC spheroids and ascitic environment in HGSOC metastasis and chemoresistance.</span></span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138573359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-08DOI: 10.1016/j.bbcan.2023.189050
Mohan Liu , Weina Hu , Xiaona Meng , Biao Wang
Cancer metastasis is a complex process influenced by various factors, including epithelial-mesenchymal transition (EMT), tumor cell proliferation, tumor microenvironment, and cellular metabolic status, which remains a significant challenge in clinical oncology, accounting for a majority of cancer-related deaths. TEAD4, a key mediator of the Hippo signaling pathway, has been implicated in regulating these factors that are all critical in the metastatic cascade. TEAD4 drives tumor metastasis and chemoresistance, and its upregulation is associated with poor prognosis in many types of cancers, making it an attractive target for therapeutic intervention. TEAD4 promotes EMT by interacting with coactivators and activating the transcription of genes involved in mesenchymal cell characteristics and extracellular matrix remodeling. Additionally, TEAD4 enhances the stemness of cancer stem cells (CSCs) by regulating the expression of genes associated with CSC maintenance. TEAD4 contributes to metastasis by modulating the secretion of paracrine factors and promoting heterotypic cellular communication. In this paper, we highlight the central role of TEAD4 in cancer metastasis and chemoresistance and its impact on various aspects of tumor biology. Understanding the mechanistic basis of TEAD4-mediated processes can facilitate the development of targeted therapies and combination approaches to combat cancer metastasis and improve treatment outcomes.
{"title":"TEAD4: A key regulator of tumor metastasis and chemoresistance - Mechanisms and therapeutic implications","authors":"Mohan Liu , Weina Hu , Xiaona Meng , Biao Wang","doi":"10.1016/j.bbcan.2023.189050","DOIUrl":"10.1016/j.bbcan.2023.189050","url":null,"abstract":"<div><p><span><span><span>Cancer metastasis<span><span> is a complex process influenced by various factors, including epithelial-mesenchymal transition (EMT), tumor cell proliferation, </span>tumor microenvironment, and cellular metabolic status, which remains a significant challenge in </span></span>clinical oncology<span>, accounting for a majority of cancer-related deaths. TEAD4, a key mediator of the Hippo signaling pathway, has been implicated in regulating these factors that are all critical in the metastatic cascade. TEAD4 drives tumor metastasis and chemoresistance, and its upregulation is associated with poor prognosis in many types of cancers, making it an attractive target for therapeutic intervention. TEAD4 promotes EMT by interacting with coactivators and activating the transcription of genes involved in mesenchymal cell characteristics and </span></span>extracellular matrix remodeling. Additionally, TEAD4 enhances the stemness of </span>cancer stem cells<span><span> (CSCs) by regulating the expression of genes associated with CSC maintenance. TEAD4 contributes to metastasis by modulating the secretion of paracrine factors and promoting heterotypic cellular communication. In this paper, we highlight the central role of TEAD4 in cancer metastasis and chemoresistance and its impact on various aspects of tumor biology. Understanding the mechanistic basis of TEAD4-mediated processes can facilitate the development of targeted therapies and combination approaches to combat cancer metastasis and improve </span>treatment outcomes.</span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138561773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-05DOI: 10.1016/j.bbcan.2023.189038
John Jimenez , Parul Dubey , Bethany Carter , John M. Koomen , Joseph Markowitz
Nitric oxide (NO) generated from nitric oxide synthase (NOS) exerts a dichotomous effect in melanoma, suppressing or promoting tumor progression. This dichotomy is thought to depend on the intracellular NO concentration and the cell type in which it is generated. Due to its central role in the metabolism of multiple critical constituents involved in signaling and stress, it is crucial to explore NO's contribution to the metabolic dysfunction of melanoma. This review will discuss many known metabolites linked to NO production in melanoma. We discuss the synthesis of these metabolites, their role in biochemical pathways, and how they alter the biological processes observed in the melanoma tumor microenvironment. The metabolic pathways altered by NO and the corresponding metabolites reinforce its dual role in melanoma and support investigating this effect for potential avenues of therapeutic intervention.
一氧化氮合酶(NOS)产生的一氧化氮(NO)在黑色素瘤中发挥着抑制或促进肿瘤进展的双重作用。这种二分法被认为取决于细胞内一氧化氮的浓度以及产生一氧化氮的细胞类型。由于 NO 在信号传导和应激过程中多种关键成分的新陈代谢中起着核心作用,因此探讨 NO 对黑色素瘤新陈代谢功能障碍的贡献至关重要。本综述将讨论许多与黑色素瘤中 NO 生成有关的已知代谢物。我们将讨论这些代谢物的合成、它们在生化途径中的作用,以及它们如何改变黑色素瘤肿瘤微环境中观察到的生物过程。氮氧化物和相应代谢物改变的代谢途径加强了氮氧化物在黑色素瘤中的双重作用,并支持研究这种作用,以寻找潜在的治疗干预途径。
{"title":"A metabolic perspective on nitric oxide function in melanoma","authors":"John Jimenez , Parul Dubey , Bethany Carter , John M. Koomen , Joseph Markowitz","doi":"10.1016/j.bbcan.2023.189038","DOIUrl":"10.1016/j.bbcan.2023.189038","url":null,"abstract":"<div><p><span><span>Nitric oxide (NO) generated from </span>nitric oxide synthase (NOS) exerts a dichotomous effect in </span>melanoma<span><span>, suppressing or promoting tumor progression. This dichotomy is thought to depend on the intracellular NO concentration and the cell type in which it is generated. Due to its central role in the metabolism of multiple critical constituents involved in signaling and stress, it is crucial to explore NO's contribution to the metabolic dysfunction of melanoma. This review will discuss many known metabolites linked to NO production in melanoma. We discuss the synthesis of these metabolites, their role in biochemical pathways, and how they alter the biological processes observed in the melanoma </span>tumor microenvironment. The metabolic pathways altered by NO and the corresponding metabolites reinforce its dual role in melanoma and support investigating this effect for potential avenues of therapeutic intervention.</span></p></div>","PeriodicalId":8782,"journal":{"name":"Biochimica et biophysica acta. Reviews on cancer","volume":null,"pages":null},"PeriodicalIF":11.2,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138557161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}